The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

Implant Clinical Trial

Official title:

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01279187
• Other study ID #: HUM00042770
• Status: Terminated
• Phase: Phase 2
• First received: January 18, 2011
• Last updated: January 31, 2018
• Start date: February 2011
• Est. completion date: November 2015

Study information

• Verified date: January 2018
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Good bone healing and bone build-up are necessary for the success of dental implants. Research in animals and humans has shown that a drug, called Forteo, can increase bone build-up and bone strength over time. Forteo has been approved by the Food and Drug Administration (FDA) for use in patients with a condition where bone is broken down and weakened, called osteoporosis. The investigators do not know, however, whether Forteo is effective for use in humans for improving bone healing after implant placement, and whether it will have the same bone-building and bone-strengthening effects as for patients with osteoporosis. This research study is being done to learn what effect 7 weeks of treatment with Forteo will have on bone build-up and strengthening of bone for patients receiving implants.

Description:

A single center, placebo-controlled, double blind parallel study of teriparatide use in patients requiring dental implant therapy is planned. Subjects who qualify based on the inclusion/exclusion criteria will be randomly placed into one of two treatment groups, teriparatide (20 μg/day) or placebo control. Both patients and investigators will be blinded. Serum and gingival crevicular fluid (GCF) samples, radiographs, and a tetracycline-labelled bone core will constitute the main data gathered for analysis. After implant surgery, patients will return at 2 weeks for post-operative care and then at 14 weeks for an implant impression and again at 16 weeks to receive the final restoration. Twelve months after implant placement, patients will be seen for a follow-up exam and standardized radiograph to ensure proper healing.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 27
• Est. completion date: November 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 85 Years

Eligibility

Inclusion Criteria:

• Age range 30-85 yrs

• Sex: male and female (female subjects must be postmenopausal, surgically sterilized or utilizing birth control or abstinence throughout the period of Teriparatide administration)

• Subjects must be able and willing to follow study procedures and instructions;

• Subjects must have read, understood and signed an informed consent form;

• Subjects must have a need for the replacement of at least one tooth in the mandibular premolar/molar region with at least 12 months since the tooth extraction.

• Sites must be adaptable for dental implant placement without the necessity for grafting.

Exclusion Criteria:

• Subjects under 30 years or over 85 years of age,

• Female subjects who are pregnant, lactating, or female subjects who are of childbearing potential who are not using contraceptives,

• Subjects with metabolic bone diseases such as Paget's disease, hypercalcemia (mild to moderate hypocalcemia is acceptable for entry into the study), moderate to severe vitamin D3 abnormalities (If vitamin D levels are below 16 ng/ml and patient exhibits interest, dietary supplementation will be suggested and levels re-evaluated after 4 weeks and reconsidered for inclusion at that time), any other metabolic bone diseases including osteoporosis,

• Subjects with prior radiation therapy, bone metastases or other skeletal malignancy,

• Subjects on medications that would affect bone metabolism,

• Subjects with growth hormone deficiency,

• Subjects with uncontrolled diabetes, sprue, inflammatory bowel disease or other disorders that would affect calcium absorption

• Subjects that are heavy smokers (> 1 pack/d),

• Subjects with tetracycline sensitivity or allergy,

• Subjects on bisphosphonates,

• Subjects with any form of kidney disease including kidney stones (urolithiasis and nephrolithiasis),

• Subjects with known allergies to tetracycline and/or demeclocycline,

Related Conditions & MeSH terms

• Implant

Intervention

Drug:
• Teriparatide
20ug per day,via subcutaneous injection, for 7 weeks
• Placebo
20ug per day, self administered injection, for 7 weeks

Locations

Country	Name	City	State
United States	Michigan Center for Oral Health Research	Ann Arbor	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
University of Michigan	Eli Lilly and Company

Country where clinical trial is conducted

United States, 

References & Publications (4)

Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005 Apr;87(4):731-41. — View Citation

Chen H, Frankenburg EP, Goldstein SA, McCauley LK. Combination of local and systemic parathyroid hormone enhances bone regeneration. Clin Orthop Relat Res. 2003 Nov;(416):291-302. — View Citation

Hanley, D., et al., Pharmacologic mechanisms of therapeutics:Parathyroid Hormone, in Principles of Bone Biology, J. Bilezikian, L. Raisz, and T. Martin, Editors. 2008, Academic Press: San Diego. p. 1661-1695.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bone Formation Rate	To determine the impact of PTH on bone quality and bone turnover in the oral cavity. The primary outcome variable will be bone formation rate.	10 weeks
Secondary	Bone Turnover (Mineral Apposition Rates)	Bone turnover was assessed indirectly by bone histomorphometry using the following abbreviations: Mineral Apposition Rate (MAR): Distance between 2 fluorochrome markers that comprise a double label on the surfaces of cancellous bone measured at an average of 4 equally-spaced sites per double label. These measurements will be performed on 20 double fluorochrome labels per bone and the average divided by the time between the midpoints of the two labeling periods. MAR serves as an index of osteoblast activity. Reported for cancellous (Cn), endocortical (Ec) at baseline (pre-drug intervention, listed as "first set") and at the end of drug intervention ("second set"). "First set" refers to baseline information (pre-drug), and "second set" refers to data evaluated at the end of the drug administration phase. Periosteal (Ps) data and Ec.Mar Endocortical MAR "second set" was reviewed but no analyzable labeling was noted and so this data is not reported.	10 weeks
Secondary	Bone Turnover: Cortical Tissue Area	Bone turnover was assessed indirectly by evaluating cellular parameters of PTH action (i.e. numbers of osteoblasts, osteoclasts, apoptotic osteoblasts). The methods used to obtain the outcomes described below were bone histomorphometry using the following abbreviation: Ct.T.Ar: Ct Cort(ex)(ical) Tissue Area (2D)b "First set" refers to baseline pre-drug data and "second set" was taken at the end of the drug administration phase.	10 weeks
Secondary	Bone Turnover: Bone Perimeter Length	Bone histomorphometry was used to assess bone perimeter length in mm as follows: Cn.Pm cancellous: Cancellous Bone Perimeter Ec.Pm: endocortical bone perimeter Ps.Pm: Periosteal Periosteal bone perimeter	10 weeks
Secondary	Bone Turnover: Bone Percentages	Oc.S/BS cancellous: Osteoclast suface divided by bone surface. Osteoclastic surface as percent of total bone surface in cancellous bone. Percent cancellous bone perimeter with osteoclasts (large, multinuclear, TRAP positive cells).; OS/BS cancellous: Osteoid surface divided by bone surface. Percentage of cancellous bone perimeter covered with osteoid.; Oc.S/BS endocortical: Osteoclastic surface as percent of total bone surface in endocortical bone.; OS/BS endocortical: Percentage of endocortical bone perimeter covered with osteoid.; Oc.S/BS Periosteal: Osteoclastic surface as percent of total bone surface in periosteal bone.; Ob.S/BS Periosteal: Percent periosteal bone perimeter with osteoid and adjacent osteoblasts, identified as plump cells with a single, eccentric nucleus and a pale-staining golgi apparatus. Osteoblast Surface divided by bone surface in periosteal bone.; OS/BS Periosteal: Percentage of periosteal bone perimeter covered with osteoid.	10 weeks